IOVA Iovance Biotherapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
13:41
Oct 11
Oct 11
IOVA buyout and re-rating expected
Sees $IOVA as a strong buyout candidate on its FDA-approved TIL therapy for metastatic melanoma and possible expansion into NSCLC, sarcoma, breast and colorectal carcinoma. Expects a buyout by 1H next year and continued re-rating as tradfi analysts recognize cellular immunotherapy's promise and profitability.
IOVA
Iovance Biotherapeutics, Inc.
Long
—
—
05:21
Oct 04
Oct 04
r/biotech_stocks
IOVA catalysts October-November, target $25-30
The author argues Iovance Biotherapeutics is set for a run driven by a cluster of catalysts: NSCLC and sarcoma data, earnings, and UK and Europe approval, all expected during October and November. The author's estimate is a move to $25-30 before the end of November, implying the catalyst cluster re-rates the stock. No specific risk is stated beyond the reliance on these catalysts materializing on schedule.
IOVA
Iovance Biotherapeutics, Inc.
Long
1ST
—
—
About IOVA Investor Commentary
Across the available history and selected sources, Buzzberg tracks IOVA (Iovance Biotherapeutics, Inc.) across 12 sources: 52 bullish vs 4 bearish calls from 18 authors. Historical directional balance: 41% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 118 total trade ideas tracked. Past 7 days, before deduplication: 3 other directions. Latest voices: CryptoCondom, u/sluthouseincel.